Use of Carbamate Compound For Preventing, Alleviating Or Treating Myotonia

Abstract

The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating myotonia.

1 - 30 . (canceled) 
     
     
         31 . A method for preventing, alleviating or treating myotonia, comprising administering to a subject in need thereof a therapeutically effective amount of a carbamate compound of the following Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof: 
       
         
           
           
               
               
           
         
         wherein, 
         R 1  and R 2  are each independently selected from the group consisting of hydrogen, halogen, C 1 -C 8  alkyl, halo-C 1 -C 8 alkyl, C 1 -C 8  thioalkoxy and C 1 -C 8 alkoxy; and 
         one of A 1  and A 2  is CH, and the other is N. 
       
     
     
         32 - 40 . (canceled) 
     
     
         41 . A method for preventing, alleviating or treating muscle stiffness, spasticity, distal muscle weakness, weakness of the face and jaw muscles, difficulty in swallowing, sagging of the eyelids (blepharosis), weakness of the neck muscles, weakness of the arm and leg muscles, persistent muscle pain, excessive sleep, muscle wasting, dysphagia, respiratory failure, irregular heartbeat, or heart muscle damage, comprising:
 administering to a subject in need thereof a therapeutically effective amount of a carbamate compound of the following Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof:   
       
         
           
           
               
               
           
         
         wherein, 
         R 1  and R 2  are each independently selected from the group consisting of hydrogen, halogen, C 1 -C 8  alkyl, halo-C 1 -C 8  alkyl, C 1 -C 8  thioalkoxy and C 1 -C 8 alkoxy; and 
         one of A 1  and A 2  is CH, and the other is N. 
       
     
     
         42 . The method according to  claim 41 , wherein R 1  and R 2  are each independently selected from the group consisting of hydrogen, halogen and C 1 -C 8  alkyl. 
     
     
         43 . The method according to  claim 41 , wherein the carbamate compound of Formula 1 is carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl-ethyl ester of the following Formula 2: 
       
         
           
           
               
               
           
         
       
     
     
         44 . The method according to  claim 41 , wherein the subject to be administered is a mammal. 
     
     
         45 . The method according to  claim 41 , wherein the therapeutically effective amount of the carbamate compound of Formula 1 is 50 to 500 mg based on the free form when administered once a day. 
     
     
         46 . The method according to  claim 41 , wherein the carbamate compound of Formula 1 is administered in a form of composition comprising at least one pharmaceutically acceptable carrier. 
     
     
         47 . The method according to  claim 46 , wherein the composition is an oral composition. 
     
     
         48 . The method according to  claim 46 , wherein the pharmaceutically acceptable carrier is one or more components selected from fillers, antioxidants, buffers, bacteriostats, dispersants, adsorbents, surfactants, binders, preservatives, disintegrants, sweeteners, flavors, glidants, release-controlling agents, wetting agents, stabilizers, suspending agents and lubricants. 
     
     
         49 . The method according to  claim 48 , wherein the fillers are selected from the group consisting of sugar, starch, sugar alcohol, starch hydrolysate, cellulose, and cellulose derivatives. 
     
     
         50 . The method according to  claim 48 , wherein the binders are selected from the group consisting of povidone, copovidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, gelatin, gum, sucrose, and starch. 
     
     
         51 . The method according to  claim 48 , wherein the preservatives are selected from the group consisting of benzoic acid, sodium benzoate, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, chlorbutol, gallate, hydroxybenzoate, and EDTA. 
     
     
         52 . The method according to  claim 48 , wherein the disintegrants are selected from the group consisting of sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, starch, and microcrystalline cellulose. 
     
     
         53 . The method according to  claim 48 , wherein the sweeteners are selected from the group consisting of sucralose, saccharin, sodium saccharin, potassium saccharin, calcium saccharin, acesulfame potassium or sodium cyclamate, mannitol, fructose, sucrose, and maltose. 
     
     
         54 . The method according to  claim 48 , wherein the glidants are selected from the group consisting of silica, colloidal silicon dioxide, and talc. 
     
     
         55 . The method according to  claim 48 , wherein the lubricants are selected from the group consisting of long chain fatty acids and salts thereof, such as magnesium stearate and stearic acid, talc, and glyceride wax.